Douglas Kling
Director de Operaciones en FRAZIER LIFESCIENCES ACQUISITION CORPORATION .
Fortuna: - $ al 31/05/2024
Cargos activos de Douglas Kling
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Director de Operaciones | 01/03/2021 | - |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Director de Operaciones | 01/03/2021 | - |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Director de Operaciones | 01/03/2021 | - |
Historial de carrera de Douglas Kling
Antiguos cargos conocidos de Douglas Kling.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Corvidia Therapeutics, Inc.
 Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01/12/2017 | 01/02/2021 |
| MATINAS BIOPHARMA HOLDINGS, INC. | Corporate Officer/Principal | 12/03/2015 | 01/11/2017 |
Omthera Pharmaceuticals, Inc.
 Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | 01/08/2010 | 01/12/2014 |
| Shionogi USA Holdings, Inc. | Corporate Officer/Principal | 01/07/2009 | 01/07/2010 |
| THE MEDICINES COMPANY | Corporate Officer/Principal | 01/04/2008 | 01/07/2009 |
Reliant Pharmaceuticals LLC
 Reliant Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Reliant Pharmaceuticals, Inc. sells, markets and develops cardiovascular pharmaceutical products. The company focuses on marketing promotionally sensitive pharmaceutical products to the primary care, cardiovascular and specialist physician markets in the United States. The company is headquartered in Liberty Corner, NJ | Corporate Officer/Principal | 01/11/2000 | 01/03/2008 |
| ░░░░░ ░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formación de Douglas Kling.
| Rutgers Business School | Masters Business Admin |
| Duke University | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 10 |
| Países Bajos | 4 |
Operativa
| Corporate Officer/Principal | 7 |
| Chief Operating Officer | 3 |
| Masters Business Admin | 1 |
Sectorial
| Health Technology | 8 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| MATINAS BIOPHARMA HOLDINGS, INC. | Health Technology |
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Health Technology |
| Empresas privadas | 8 |
|---|---|
Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Health Technology |
| Shionogi USA Holdings, Inc. | |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Reliant Pharmaceuticals LLC
Reliant Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Reliant Pharmaceuticals, Inc. sells, markets and develops cardiovascular pharmaceutical products. The company focuses on marketing promotionally sensitive pharmaceutical products to the primary care, cardiovascular and specialist physician markets in the United States. The company is headquartered in Liberty Corner, NJ | Commercial Services |
| Knoll Pharmaceutical Co. | |
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Health Technology |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Health Technology |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Douglas Kling
- Experiencia
